A Phase 1/2 interventional study of 400 µg Brimonidine Tartrate Implant and 200 µg Brimonidine Tartrate Implant in Retinitis Pigmentosa, sponsored by Allergan. Completed at 4 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-04-24.
Sponsored by Allergan (part of AbbVie) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 119 studies in Retinitis Pigmentosa with a site in United States — 20 open to participants now, 44 under way, 6 of them phase 3. Retinitis Pigmentosa · United States.
Among the 119 studies in Retinitis Pigmentosa with a site in United States, this one is the 39th largest by enrollment of the 78 interventional ones that give a count, is the only one that started in 2008, is one of 20 in phase 1/2, and was the 22nd registered.
278 studies on the registry are indexed under Retinitis Pigmentosa; 72 are open to participants now.
Browse Retinitis Pigmentosa studies →20 of the 119 studies in Retinitis Pigmentosa with a site in United States are open now. Recruiting first, the newest first:
Nacuity Pharmaceuticals, Inc. · Sites in United States
Ages 18+
Ray Therapeutics, Inc. · Sites in United States
Ages 18+
Sumitomo Pharma America, Inc. · Sites in United States
Ages 18+
Octant, Inc. · Sites in United States
Ages 18+
Ray Therapeutics, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 49 Retinitis Pigmentosa studies recruiting now, 37 (76%) set no upper age limit and 7 (14%) stop at 75 or younger; 16 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
119 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 34 · Phase 2 38 · Phase 3 11
First in 1993; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 21 is below the median of 27 across 179 interventional studies indexed under Retinitis Pigmentosa.
Median enrollment 21 across the 78 interventional studies, 73 across the 38 observational. Of the 69 that completed or were terminated, 30 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
60 of 119 have an industry lead sponsor. The 10 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
AbbVie has 2 studies filed under Retinitis Pigmentosa — fewer than ten, so there is no comparison to draw.
11 of the studies in Retinitis Pigmentosa with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06388200Phase 3OcugenA Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa | 2027-02-12 |
| NCT06912633jCyte, IncSafety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP) | 2026-12 |
| NCT02086890Nova Southeastern UniversityElectro-acupuncture and Transcorneal Electrical Stimulation (TES) for Retinitis Pigmentosa | 2026-12 |
| NCT04278131Bionic Sight LLCBS01 in Patients With Retinitis Pigmentosa | 2026-12-30 |
| NCT05748873SparingVisionPromising ROd-cone DYstrophy Gene therapY | 2027-02 |
Add all 11 to your calendar (.ics) → With an account.
Among the 119 studies in Retinitis Pigmentosa with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This exploratory, 12-month, ascending-dose study will evaluate the safety and effects on visual function of a single injection of Brimonidine intravitreal implant in one eye of patients with Retinitis Pigmentosa.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
400 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.
Drug: 400 µg Brimonidine Tartrate Implant · Other: Sham (no implant)
200 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.
Drug: 200 µg Brimonidine Tartrate Implant · Other: Sham (no implant)
100 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.
Drug: 100 µg Brimonidine Tartrate Implant · Other: Sham (no implant)
100 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.
Drug: 100 µg Brimonidine Tartrate Implant · Other: Sham (no implant)
400 µg brimonidine tartrate implant in the study eye on Day 1.
Also known as: Brimonidine Tartrate PS DDS®
200 µg brimonidine tartrate implant in the study eye on Day 1.
Also known as: Brimonidine Tartrate PS DDS®
100 µg brimonidine tartrate implant in the study eye on Day 1.
Also known as: Brimonidine Tartrate PS DDS®
Sham in the fellow eye on Day 1.
Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye
BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening.
Time frame: Baseline, Month 6
Change From Baseline in Contrast Sensitivity in the Study Eye
Change from baseline in contrast sensitivity in the study eye is measured using a Pelli-Robson contrast sensitivity chart at 1 meter. The contrast sensitivity chart contains letters that are darkest at the top and then get progressively lighter. Scores range from 0 to 48 and are based on the number of letters read correctly. A negative change from baseline indicates a worsening in contrast sensitivity and a positive change from baseline indicates an improvement.
Time frame: Baseline, Month 6
| Milestone | 400 µg Brimonidine Tartrate Implant Group B | 200 µg Brimonidine Tartrate Implant Group B | 100 µg Brimonidine Tartrate Implant Group B | 100 µg Brimonidine Tartrate Implant Group A |
|---|---|---|---|---|
| Started | 12 | 3 | 3 | 3 |
| Completed | 12 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 |
BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening.
| Number of Letters Read Correctly | 400 µg Brimonidine Tartrate Implant Group B | 200 µg Brimonidine Tartrate Implant Group B | 100 µg Brimonidine Tartrate Implant Group B | 100 µg Brimonidine Tartrate Implant Group A |
|---|---|---|---|---|
| Baseline | 48.5 ± 14.61 | 51.0 ± 14.18 | 52.7 ± 3.79 | 4.0 ± 3.46 |
| Change from Baseline at Month 6 | 3.2 ± 4.41 | -1.3 ± 4.04 | 3.3 ± 8.50 | 0.3 ± 3.79 |
Change from baseline in contrast sensitivity in the study eye is measured using a Pelli-Robson contrast sensitivity chart at 1 meter. The contrast sensitivity chart contains letters that are darkest at the top and then get progressively lighter. Scores range from 0 to 48 and are based on the number of letters read correctly. A negative change from baseline indicates a worsening in contrast sensitivity and a positive change from baseline indicates an improvement.
| Number of Letters Read Correctly | 400 µg Brimonidine Tartrate Implant Group B | 200 µg Brimonidine Tartrate Implant Group B | 100 µg Brimonidine Tartrate Implant Group B | 100 µg Brimonidine Tartrate Implant Group A |
|---|---|---|---|---|
| Baseline | 15.5 ± 8.48 | 18.0 ± 7.21 | 22.3 ± 1.53 | 3.0 ± 3.46 |
| Change from Baseline at Month 6 | 0.8 ± 4.86 | -0.3 ± 5.86 | 4.3 ± 1.15 | -2.0 ± 1.73 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 400 µg Brimonidine Tartrate Implant Group B | — | 1/12 (8.3%) | 11/12 (91.7%) |
| 200 µg Brimonidine Tartrate Implant Group B | — | 0/3 (0%) | 3/3 (100%) |
| 100 µg Brimonidine Tartrate Implant Groups A and B | — | 1/6 (16.7%) | 6/6 (100%) |
| Event | 400 µg Brimonidine Tartrate Implant Group B | 200 µg Brimonidine Tartrate Implant Group B | 100 µg Brimonidine Tartrate Implant Groups A and B |
|---|---|---|---|
| MyelitisNervous system disorders | 0/12 | 0/3 | 1/6 |
| SyncopeNervous system disorders | 1/12 | 0/3 | 0/6 |
| Event | 400 µg Brimonidine Tartrate Implant Group B | 200 µg Brimonidine Tartrate Implant Group B | 100 µg Brimonidine Tartrate Implant Groups A and B |
|---|---|---|---|
| Conjunctival HyperaemiaEye disorders | 5/12 | 3/3 | 5/6 |
| Conjunctival HaemorrhageEye disorders | 5/12 | 2/3 | 1/6 |
| Conjunctival OedemaEye disorders | 2/12 | 2/3 | 1/6 |
| NasopharyngitisInfections and infestations | 3/12 | 0/3 | 2/6 |
| Eye PainEye disorders | 2/12 | 0/3 | 2/6 |
| Prostate InfectionInfections and infestations | 0/7 | 0/2 | 1/3 |
| ConjunctivitisEye disorders | 0/12 | 1/3 | 0/6 |
| Dental CariesGastrointestinal disorders | 0/12 | 1/3 | 0/6 |
| PharyngitisInfections and infestations | 0/12 | 1/3 | 0/6 |
| Foreign Body Sensation in EyesEye disorders | 3/12 | 0/3 | 1/6 |
| Age Continuous(Years) | 400 µg Brimonidine Tartrate Implant Group B | 200 µg Brimonidine Tartrate Implant Group B | 100 µg Brimonidine Tartrate Implant Group B | 100 µg Brimonidine Tartrate Implant Group A | Total |
|---|---|---|---|---|---|
| Mean | 46.3 ± 18.70 | 56.3 ± 6.03 | 48.7 ± 4.04 | 69.0 ± 5.29 | 51.3 ± 16.36 |
| Sex: Female, Male(Participants) | 400 µg Brimonidine Tartrate Implant Group B | 200 µg Brimonidine Tartrate Implant Group B | 100 µg Brimonidine Tartrate Implant Group B | 100 µg Brimonidine Tartrate Implant Group A | Total |
|---|---|---|---|---|---|
| Female | 5 | 1 | 3 | 0 | 9 |
| Male | 7 | 2 | 0 | 3 | 12 |
The record gives a start of Jul 2008, a primary completion of Dec 2009 and a completion of May 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2013, 3 years 4 months after primary completion. A results delay was requested in Feb 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brimonidine